Rilmenidine in the hypertensive type-2 diabetic: A controlled pilot study versus captopril

European Journal of Preventive Cardiology

Volumn 7, Issue 1, 2000, Pages 57-61

  Bauduceau, Bernard ^a   Mayaudon, Hervé ^a   Dupuy, Olivier ^a  

^a SERVICE D ENDOCRINOLOGIE   (France)

Author keywords

captopril; hypertension; microalbuminuria; rilmenidine; type 2 diabetes mellitus

Indexed keywords

CAPTOPRIL; RILMENIDINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CAPTOPRIL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXAZOLES; PILOT PROJECTS;

EID: 84992884135     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748730000700110     Document Type: Article

References (15)

1. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–317.
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–360.
3. Head G. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anesthetized rabbit. J Hypertens 1998; 16: 503–517.
4. Kline RL, Cechetto DF. Natriuretic effect of rilmenidine in anesthetized rats. Am J Cardiol 1994; 74: 20A–24A.
5. Smyth D, Penner S. Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. J Cardiovasc Pharmacol 1995; 26 (suppl 2): S63–S67.
6. Bricca G, Greney H. Human brain imidazoline receptors: further characterization with 3H clonidine. Eur J Pharmacol 1994; 266: 25–33.
7. Senechau P, Bousquet P, Dontenwill M. Imidazoline specific binding sites in the human kidney. Arch Pharmacol 1998; 358 (suppl 2): R747.
8. Lubetzki J. Safety and efficacy of rilmenidine in hypertensive type 2 diabetics [Expert report of rilmenidine's registration file submitted in 1986 to French Authorities].
9. Marre M, Claudel JP, Ciret P. Immunonephelometry for routine quantification of urinary albumin excretion. Clin Chem 1987; 33: 209–213.
10. Lewis E, Hunsicker L, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.
11. Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985; 7 (suppl II): 109–113.
12. Parving HH. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996; 14 (suppl 2): S89–S94.
13. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703–713.
14. Luccioni R. Evaluation pharmacoépidémiologique de la rilmenidine chez 18235 hypertendus. Presse Méd 1995; 24: 1857–1864.
15. Pelemans W. Efficacy and safety of rilmenidine in elderly patients: comparison with hydrochlorothiazide. Am J Cardiol 1994; 74: 51A–57A.